Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

575.63 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
49 50 Next >
Celldex Makes A Bullish Move As It Looks To Take On Regeneron, Sanofi
The company is looking to take on Regeneron and Sanofi's Dupixent in skin diseases. 
Via Investor's Business Daily
Why Is Eye Disease-Focused Adverum Bio Stock Trading Higher Today?
Adverum Biotechnologies Inc (NASDAQ: ADVM) revealed updated data from the OPTIC extension study of ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) in patients with wet AMD during... 
Via Benzinga
Regeneron Pharmaceuticals Stock Upgraded After Q3, But There Is A Headwind - Analyst Review
Thursday, Regeneron Pharmaceuticals Inc (NASDAQ: REGN) reported better-than- 
Via Benzinga
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
Regeneron Edges Higher On Third-Quarter Beat As High-Dose Eylea Delivers
The launch of high-dose Eylea is off to a strong start in the U.S. 
Via Investor's Business Daily
Regeneron Pharmaceuticals Unusual Options Activity
Via Benzinga
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) earned Q3 adjusted EPS of $11.59, up 4% Y/Y, beating the $10.77 Street estimate 
Via Benzinga
US Stocks On Track For Solid Start Amid Lingering Fed Optimism: Traders Eye Earnings From Market Bellwether Apple
After the Federal Reserve‘s decision, the stock market rally is poised to gain momentum on Thursday, with stock futures indicating an uptick. 
Via Benzinga
Topics Economy
Exposures Interest Rates
$100 Invested In Regeneron Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week
S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week. 
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today
Via Benzinga
1 Supercharged Growth Stock That Could Make You a Millionaire in 10 Years
Biotech may be in a slump, but this innovator holds enormous promise as a potential wealth escalator. 
Via The Motley Fool
Regeneron Reports Third Quarter 2023 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Data Presentations at AAO Reinforce Efficacy and Safety Profile in Wet Age-related Macular Degeneration and Diabetic Macular Edema
Long-term data and subgroup analyses from pivotal EYLEA HD clinical program highlight durability of visual improvements and consistent safety across extended dosing intervals and patient... 
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Healthcare Playbook: Hardly Defensive With A Covid Hangover In Biotech
Market Bubbles may take a long time to clear and we created a big one in July 2021 dealing with the COVID pandemic. 
Via Talk Markets
Exposures COVID-19
Earnings Scheduled For November 2, 2023
Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million. 
Via Benzinga
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.  
Via Benzinga
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
The U.S. 
Via Benzinga
Exposures Product Safety
SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff
The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year. 
Via InvestorPlace
Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
IBD's 100 Best ESG Companies For 2023
The companies on our list combine high sustainability scores and top stock ratings. 
Via Investor's Business Daily
Regeneron Announces Investor Conference Presentations
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Stock-Split Watch: Could These 2 Growth Stocks Be Next?
Neither company has discussed it, at least not yet. 
Via The Motley Fool
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
The venerable pharmaceutical companies' shares have slumped this year. 
Via The Motley Fool
Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
49 50 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.